The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant?∗

Patrick M. Kochanek; Jeremy R. Herrmann; Thomas P. Bleck

doi:10.1097/CCM.0000000000005826

The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant?∗

Patrick M. Kochanek, Jeremy R. Herrmann, Thomas P. Bleck

Neurology

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	677-680
Number of pages	4
Journal	Critical care medicine
Volume	51
Issue number	5
DOIs	https://doi.org/10.1097/CCM.0000000000005826
State	Published - May 1 2023

Funding

Dr. Kochanek’s institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann’s institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400. Dr. Kochanek's institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann's institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400.

Keywords

cerebral blood flow
children
head trauma
intracranial pressure
seizure
spreading depolarization

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine

Access to Document

10.1097/CCM.0000000000005826

Cite this

@article{ae75289bb1ca4972aafc0346011f6ac7,

title = "The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant?∗",

keywords = "cerebral blood flow, children, head trauma, intracranial pressure, seizure, spreading depolarization",

author = "Kochanek, {Patrick M.} and Herrmann, {Jeremy R.} and Bleck, {Thomas P.}",

note = "Funding Information: Dr. Kochanek{\textquoteright}s institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann{\textquoteright}s institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400. Funding Information: Dr. Kochanek's institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann's institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400.",

year = "2023",

month = may,

day = "1",

doi = "10.1097/CCM.0000000000005826",

language = "English (US)",

volume = "51",

pages = "677--680",

journal = "Critical care medicine",

issn = "0090-3493",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant?∗

AU - Kochanek, Patrick M.

AU - Herrmann, Jeremy R.

AU - Bleck, Thomas P.

N1 - Funding Information: Dr. Kochanek’s institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann’s institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400. Funding Information: Dr. Kochanek's institution received funding from the National Institutes of Health (NIH) and the U.S. Army; he received funding from lectures at national meetings and/or as a guest professor at various institutions of higher education and for editing or authoring books and/or chapters; and he disclosed that he has served as an expert witness on several cases over the past 36 months and has multiple patents. Dr. Herrmann's institution received funding from the NIH (T32 HD040686), the Safar Center for Resuscitation Research, the Zoll Foundation, and the Laerdal Foundation. Dr. Hermann received support for article research from the NIH. Dr. Bleck received funding from Marinus Pharmaceuticals and the American Board of Internal Medicine; he disclosed the off-label product use of ketamine in head injury; and he is supported by NIH grant DP2HD101400.

PY - 2023/5/1

Y1 - 2023/5/1

KW - cerebral blood flow

KW - children

KW - head trauma

KW - intracranial pressure

KW - seizure

KW - spreading depolarization

UR - http://www.scopus.com/inward/record.url?scp=85152600372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152600372&partnerID=8YFLogxK

U2 - 10.1097/CCM.0000000000005826

DO - 10.1097/CCM.0000000000005826

M3 - Editorial

C2 - 37052437

AN - SCOPUS:85152600372

SN - 0090-3493

VL - 51

SP - 677

EP - 680

JO - Critical care medicine

JF - Critical care medicine

IS - 5

ER -

The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant?∗

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this